NCT04272333 - Intratumoral Microdosing of Motolimod in HNSCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

March 25, 2022

Study Completion Date

March 25, 2022

Conditions

HNSCC

Interventions

DRUG

Motolimod

Intratumoral microdose injection by the CIVO device.

BIOLOGICAL

Nivolumab

Intratumoral microdose injection by the CIVO device.

COMBINATION_PRODUCT

Motolimod + Nivolumab

Intratumoral microdose injection by the CIVO device.

Trial Locations (5)

Wake Forest Baptist Health, Winston-Salem

University of Illinois at Chicago, Chicago

University of California, San Francisco, San Francisco

Oregon Health & Science University (OHSU), Portland

Portland VA, Portland